InDex Pharmaceuticals Holding AB (SE:FLERIE)
:FLERIE
Top Page
InDex Pharmaceuticals Holding AB
(FLERIE)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr30.00
▼(-19.46% Downside)
Action:ReiteratedDate:04/02/26
The score is driven primarily by weak financial performance—large losses, volatile revenue, and persistent operating cash outflows—despite low balance-sheet leverage. Technicals add downside pressure with a clear downtrend and negative momentum, while valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Low leverage
The company’s very low debt profile provides a durable solvency buffer that reduces near-term default risk and interest burden. This conservative capital structure gives management time to execute R&D or commercialization plans without immediate debt-driven liquidity pressure, supporting long-term optionality.
Negative Factors
Persistent cash burn
Consistent negative operating cash flow demonstrates structural cash consumption to run the business, forcing reliance on external financing. Over months this erodes liquidity, raises dilution or refinancing risk, and constrains ability to invest organically until operations generate sustainable positive cash flow.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
The company’s very low debt profile provides a durable solvency buffer that reduces near-term default risk and interest burden. This conservative capital structure gives management time to execute R&D or commercialization plans without immediate debt-driven liquidity pressure, supporting long-term optionality.
Read all positive factors
InDex Pharmaceuticals Holding AB (FLERIE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr2.29B
Dividend YieldN/A
Average Volume (3M)10.31K
Price to Earnings (P/E)―
Beta (1Y)0.22
Revenue Growth-35.98%
EPS Growth-102.62%
CountrySE
Employees8
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-6.99
Shares Outstanding79,643,010
10 Day Avg. Volume8,358
30 Day Avg. Volume10,307
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.86
Price to Sales (P/S)331.74
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
InDex Pharmaceuticals Holding AB Business Overview & Revenue Model
Company Description
Flerie AB (publ) is a venture capital firm specializing in early-stage investments. It seeks to invest in biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. ...
How the Company Makes Money
null...
InDex Pharmaceuticals Holding AB Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.80M | 100.00K | 97.50M | 0.00 | 0.00 |
| Gross Profit | -12.70M | -41.60M | 93.35M | -1.07M | -1.25M |
| EBITDA | -743.60M | -225.90M | -93.82M | -99.15M | -101.66M |
| Net Income | -756.90M | -228.00M | -95.27M | -100.33M | -103.04M |
Balance Sheet | |||||
| Total Assets | 3.40B | 4.22B | 299.39M | 351.34M | 445.20M |
| Cash, Cash Equivalents and Short-Term Investments | 540.20M | 865.10M | 294.27M | 344.93M | 428.45M |
| Total Debt | 3.70M | 800.00K | 2.30M | 3.25M | 1.28M |
| Total Liabilities | 20.30M | 25.30M | 60.50M | 17.38M | 11.16M |
| Stockholders Equity | 3.38B | 4.20B | 238.88M | 333.96M | 434.04M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -17.00M | -37.98M | -129.44M | -124.06M |
| Operating Cash Flow | -28.10M | -17.00M | -37.98M | -129.44M | -124.06M |
| Investing Cash Flow | -109.50M | -19.80M | -625.20M | 0.00 | 0.00 |
| Financing Cash Flow | -195.50M | 571.90M | 634.70M | -818.00K | 486.39M |
InDex Pharmaceuticals Holding AB Technical Analysis
Negative
37.25
Price Trends
35.26
Negative
36.48
Negative
39.58
Negative
Market Momentum
-1.07
Positive
24.74
Positive
12.02
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLERIE, the sentiment is Negative. The current price of 37.25 is above the 20-day moving average (MA) of 34.55, above the 50-day MA of 35.26, and below the 200-day MA of 39.58, indicating a bearish trend. The MACD of -1.07 indicates Positive momentum. The RSI at 24.74 is Positive, neither overbought nor oversold. The STOCH value of 12.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:FLERIE.
InDex Pharmaceuticals Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr966.34M | -10.42 | -58.41% | ― | ― | 48.14% | |
55 Neutral | kr881.32M | 103.06 | 6.93% | ― | -5.80% | -65.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr2.82B | -5.68 | -49.96% | ― | -91.85% | -6.65% | |
45 Neutral | kr1.18B | -7.05 | -35.03% | ― | ― | 25.14% | |
44 Neutral | kr2.29B | -3.86 | -19.71% | ― | -35.98% | -102.62% | |
42 Neutral | kr26.30M | -0.24 | -186.13% | ― | ― | 0.30% |
* Healthcare Sector Average
SE:FLERIE
InDex Pharmaceuticals Holding AB
28.80
-10.96
-27.56%
SE:SYNACT
SynAct Pharma AB
18.12
0.44
2.49%
SE:CRAD.B
C-Rad AB Class B
26.10
-0.60
-2.25%
SE:VICO
Vicore Pharma Holding AB
10.00
3.67
57.98%
SE:GUARD
Guard Therapeutics International AB
1.30
-10.60
-89.04%
SE:XSPRAY
Xspray Pharma AB
25.60
-1.62
-5.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.